U.S. Markets closed

Progenics Pharmaceuticals, Inc. (PGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.1000-0.4250 (-9.39%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.5250
Bid0.0000 x 3100
Ask0.0000 x 41800
Day's Range4.0100 - 4.7900
52 Week Range1.8900 - 6.3700
Avg. Volume0
Market Cap355.046M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
  • Lantheus Holdings Inc (LNTH) Q3 2020 Earnings Call Transcript
    Motley Fool

    Lantheus Holdings Inc (LNTH) Q3 2020 Earnings Call Transcript

    In particular, the continuing impact of COVID-19 on our business results and outlook is a best estimate based on the information available as of today's date. With me on today's call are Mary Anne Heino, our President, and CEO; and Bob Marshall, our Chief Financial Officer. Mary Anne will begin with some introductory remarks and a business update and then Bob will cover our financial results.

  • Lantheus Holdings Inc (LNTH) Q2 2020 Earnings Call Transcript
    Motley Fool

    Lantheus Holdings Inc (LNTH) Q2 2020 Earnings Call Transcript

    Joining me today is our President and CEO, Mary Anne Heino, and our CFO, Bob Marshall. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements due to a variety of risks and uncertainties.

  • Lantheus Completes Merger with Progenics
    Business Wire

    Lantheus Completes Merger with Progenics

    Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc. ("Progenics") (Nasdaq: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. The merger agreement was first announced on October 2, 2019.